Nasal Polyps Treatment Market
The healthcare industry is primarily driven by constant research experiments, and the nasal polyps treatment market is no exception, as it is evolving rapidly with the unique outcomes of these studies to improve the effectiveness of therapies. Extensive studies on nasal polyps are leading to new treatment opportunities for health conditions such as asthma, sinusitis, allergies, and more. These studies are laying the foundation for understanding the causes of developing nasal polyps, and introducing more effective treatments in this landscape.
Recently, NIAID (National Institute of Allergy and Infectious Diseases) initiated a study to understand the causes of, and ultimately develop treatments for nasal polyps. The study found that, exposure of the epithelial cells to Dupilumab, a drug used to treat patients suffering from asthma and allergic inflammation, can influence shifts in gene expression and cell behavior. However, the study also found that, the same impact was not completely observed on several polyp-associated genes, suggesting the need for innovation in nasal polyps treatments that can also be effective on other polyps-related diseases.
Studies have also found that, the prevalence of chronic rhinosinusitis with nasal polyps is increasing, and patients are tied to a high risk of depression and anxiety. This is creating the need for chronic rhinosinusitis treatments as well as medications that can shrink the size of nasal polyps while facilitating the treatment for rhinosinusitis, which is likely to incur transformational changes in the way nasal polyps are treated, in the coming years.
In terms of scope for the nasal polyps treatment market, the growth indicator is projected to show an immense rise in the coming years. The market is currently valued at ~US$ 3.9 billion, and is likely to reach ~US$ 4 billion by 2019 end. An increasing number of ongoing studies is expected to drive the rising tide of innovation in this landscape, and the nasal polyps treatment market is expected to witness impressive growth in the coming decade.
Identify the key factors that will drive your company’s growth. Request a brochure of this report here
Patients’ preferences, shifting away from invasive treatments to non-invasive treatments, are having a significant impact on the emerging trends in the nasal polyps treatment market. Though the market is predominantly subjugated by pharmacological therapies such as corticosteroids, antibiotics, leukotriene inhibitors, hospitals and specialty clinics are also aiming to offer minimally-invasive surgical treatments that can cure, not only nasal polyps, but also various other health complications caused due to nasal polyps.
Functional endoscopic sinus surgery (FESS)—a minimally-invasive surgical treatment for nasal polyps—is emerging as one of the most favored nasal polyps treatments by patients as well as medical professionals. Its adoption over invasive surgical treatments such as polypectomy surgery of nasal polyps, is mainly attributed to its minimally-invasive nature that allows surgeons to directly visualize the critical areas of the nasal passage, which signifies more comfort and efficiency for both, patients and medical professionals.
Though the rising pervasiveness of asthma, nasal polys, and sinusitis has led to an increase in the efforts for the development of novel, non-invasive therapies, many nasal polyps treatments are challenged by bygone therapies such as systemic or oral corticosteroids and intranasal sprays. Stakeholders are focusing on their novel therapies and treatments in the pipeline that can prove more effective and efficient than the ones that are already popular in the market. For instance, GlaxoSmithKline – a British multinational pharmaceutical company – announced that the European Commission has approved Nucala (mepolizumab), a targeted monoclonal antibody for the treatment of various health conditions, and is in the pipeline for further investigation for the treatment of nasal polyposis.
Want to know more such detailed insights of “Nasal Polyps Treatment Market”? Request a PDF sample here?
Although the number of stakeholders entering the nasal polyps treatment market is increasing rapidly, resistances such as inefficacy of pharmacological therapies, high cost of treatment, and complications associated with sinus surgeries are expected to slow down the growth of the nasal polyps treatment market in the coming years. These restraints are a result of common fears pertaining to steroid therapy, and the high risk of side effects such as weight gain, loss of bone mineral density, and cataract formation in the eyes.
In addition, some of the complications subject to sinus surgeries are excessive bleeding, cerebrospinal fluid leak, visual disturbances, postoperative scarring, and inflammation. Also the expensive procedure associated with functional endoscopic sinus surgery (FESS) as compared to other low-cost alternatives such as courses of intranasal sprays, and the recurrence of diseases post-surgery, are hindering the growth prospects of surgical treatments in the global nasal polyps treatment market.
However, key competitors are strategically tackling these issues by broadening their product portfolios for nasal polyps therapies, and introducing innovative treatments that are cost-efficient as well as more effective, to secure their position as leading players in the nasal polyps treatment market. For example, in September 2018, Novartis International AG – a leading a Swiss multinational pharmaceutical company – announced that it has received an approval from the U.S Food and Drug Administration (FDA) for 75 mg/0.5 mL and 150 mg/1 mL single-dose prefilled syringes (PFS), which are used as an add-on formulation for both, chronic idiopathic urticaria (CIU) and allergic asthma indications with its new product – Xolair (Omalizumab).
Expanding operations in future? To get the perfect launch ask for a custom report here
Analysts’ View of the Nasal Polyps Treatment Market
Authors of this report anticipate a favorable growth landscape for the nasal polyps treatment market over the forecast period of 2019–2027. The market is projected to expand its boundaries in North America, Asia Pacific, and Europe, with ongoing research directed towards introducing efficient treatments for nasal polyps, as well as other respiratory diseases triggered by the condition. The adoption of minimally-invasive surgical treatments is expected to increase among healthcare organizations; ambulatory surgical centers are projected to headline the winning race in the competitive landscape.
Functional endoscopic sinus surgery (FESS) and other less-invasive surgeries are gaining traction among consumers as well as manufacturers. However common fears and stigma attached to steroid therapies, low-cost alternatives, short-term solutions, and recurrence of diseases post-surgery are some of the hindrances that are affecting the nasal polyps treatment market.
To deal with these challenges, market players must focus on prioritizing investments toward research & development to diversify their range of nasal polyps treatments. In addition, improving awareness about the efficacy of their products among end users will become inevitable, and collaborating with key players to co-promote novel treatments will help them improve their sales performance in this landscape.
Global Nasal Polyps Treatment Market: Overview
Global Nasal Polyps Treatment Market: Drivers & Restraints
Global Nasal Polyps Treatment Market: Market Segmentation
Global Nasal Polyps Treatment Market: Regional Segmentation
Global Nasal Polyps Treatment Market: Major Players
Key players operating in the global nasal polyps treatment market include
These companies have diverse portfolios of nasal polyps treatments along with a strong presence across the globe.
Segmentation of the Nasal Polyps Treatment Market
TMR’s study on the nasal polyps treatment market includes information bifurcated into three sections - by type of treatment, by end user, and by region. Changing industry trends and other crucial market dynamics associated with these sections of the nasal polyps treatment market are discussed in detail.
|
Type of Treatment |
Pharmacological Therapies
Surgeries
|
|
End User |
Hospitals Ambulatory Surgical Centers Specialty Clinics |
|
Region |
North America Europe Asia Pacific Latin America Middle East & Africa |
Nasal polyps treatment market to reach a value of ~ US$ 6 Bn by 2027
Nasal polyps treatment market is projected to expand at a CAGR of ~5% from 2019 to 2027
Nasal polyps treatment market is driven by rise in prevalence of CRSwNP across the globe
The pharmacological therapies segment dominated the global nasal polyps treatment market, and the trend is projected to continue during the forecast period
Key players in the global nasal polyps treatment market include are Merck & Co, Inc., Intersect ENT, Inc., OptiNose US, Inc., Sanofi, Pfizer, GlaxoSmithKline plc
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Nasal Polyps Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Treatment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Nasal Polyps Treatment Market Analysis and Forecast, 2017–2027
4.4.1. Market Revenue Projections (US$ Mn)
5. Market Outlook
5.1. Key Industry Developments
5.2. Pipeline Analysis
5.3. Qualitative Assessment on Novel Treatment Options for Nasal Polyps: Biologics & Stents
5.3.1. Key Insights on Biologics (Xolair, Dupixent, Nucala)
6. Global Nasal Polyps Treatment Market Analysis and Forecast, by Type of Treatment
6.1. Introduction & Definition
6.2. Market Value Forecast, by Type of Treatment , 2017–2027
6.2.1. Pharmacological Therapies
6.2.1.1. Corticosteroids
6.2.1.2. Antibiotics
6.2.1.3. Leukotriene Inhibitors
6.2.1.4. Others
6.2.2. Surgeries
6.2.2.1. Polypectomy
6.2.2.2. Functional Endoscopic Sinus Surgery (FESS)
6.3. Market Attractiveness By Type of Treatment
7. Global Nasal Polyps Treatment Market Analysis and Forecast, by End-user
7.1. Introduction & Definition
7.2. Market Value Forecast, by End-user, 2017–2027
7.2.1. Hospitals
7.2.2. Ambulatory Surgical Centers
7.2.3. Specialty Clinics
7.3. Market Attractiveness, by End-user
8. Global Nasal Polyps Treatment Market Analysis and Forecast, by Region
8.1. Introduction
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Country/Region
9. North America Nasal Polyps Treatment Market Analysis and Forecast
9.1. Introduction
9.2. Market Value Forecast, by Type of Treatment , 2017–2027
9.2.1. Pharmacological Therapies
9.2.1.1. Corticosteroids
9.2.1.2. Antibiotics
9.2.1.3. Leukotriene Inhibitors
9.2.1.4. Others
9.2.2. Surgeries
9.2.2.1. Polypectomy
9.2.2.2. Functional Endoscopic Sinus Surgery (FESS)
9.3. Market Value Forecast, by End-user, 2017–2027
9.3.1. Hospitals
9.3.2. Ambulatory Surgical Centers
9.3.3. Specialty Clinics
9.4. Market Value Forecast, by Country, 2017–2027
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Type of Treatment
9.5.2. By End-user
9.5.3. By Country
10. Europe Nasal Polyps Treatment Market Analysis and Forecast
10.1. Introduction
10.2. Market Value Forecast, by Type of Treatment , 2017–2027
10.2.1. Pharmacological Therapies
10.2.1.1. Corticosteroids
10.2.1.2. Antibiotics
10.2.1.3. Leukotriene Inhibitors
10.2.1.4. Others
10.2.2. Surgeries
10.2.2.1. Polypectomy
10.2.2.2. Functional Endoscopic Sinus Surgery (FESS)
10.3. Market Value Forecast, by End-user, 2017–2027
10.3.1. Hospitals
10.3.2. Ambulatory Surgical Centers
10.3.3. Specialty Clinics
10.4. Market Value Forecast, by Country/Sub-region, 2017–2027
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Type of Treatment
10.5.2. By End-user
10.5.3. By Country/Sub-region
11. Asia Pacific Nasal Polyps Treatment Market Analysis and Forecast
11.1. Introduction
11.2. Market Value Forecast, by Type of Treatment, 2017–2027
11.2.1. Pharmacological Therapies
11.2.1.1. Corticosteroids
11.2.1.2. Antibiotics
11.2.1.3. Leukotriene Inhibitors
11.2.1.4. Others
11.2.2. Surgeries
11.2.2.1. Polypectomy
11.2.2.2. Functional Endoscopic Sinus Surgery (FESS)
11.3. Market Value Forecast, by End-user, 2017–2027
11.3.1. Hospitals
11.3.2. Ambulatory Surgical Centers
11.3.3. Specialty Clinics
11.4. Market Value Forecast, by Country/Sub-region, 2017–2027
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Type of Treatment
11.5.2. By End-user
11.5.3. By Country/Sub-region
12. Latin America Nasal Polyps Treatment Market Analysis and Forecast
12.1. Introduction
12.2. Market Value Forecast, by Type of Treatment, 2017–2027
12.2.1. Pharmacological Therapies
12.2.1.1. Corticosteroids
12.2.1.2. Antibiotics
12.2.1.3. Leukotriene Inhibitors
12.2.1.4. Others
12.2.2. Surgeries
12.2.2.1. Polypectomy
12.2.2.2. Functional Endoscopic Sinus Surgery (FESS)
12.3. Market Value Forecast, by End-user, 2017–2027
12.3.1. Hospitals
12.3.2. Ambulatory Surgical Centers
12.3.3. Specialty Clinics
12.4. Market Value Forecast, by Country/Sub-region, 2017–2027
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Type of Treatment
12.5.2. By End-user
12.5.3. By Country/Sub-region
13. Middle East & Africa Nasal Polyps Treatment Market Analysis and Forecast
13.1. Introduction
13.2. Market Value Forecast, by Type of Treatment , 2017–2027
13.2.1. Pharmacological Therapies
13.2.1.1. Corticosteroids
13.2.1.2. Antibiotics
13.2.1.3. Leukotriene Inhibitors
13.2.1.4. Others
13.2.2. Surgery
13.2.2.1. Polypectomy
13.2.2.2. Functional Endoscopic Sinus Surgery (FESS)
13.3. Market Value Forecast, by End-user, 2017–2027
13.3.1. Hospitals
13.3.2. Ambulatory Surgical Centers
13.3.3. Specialty Clinics
13.4. Market Value Forecast, by Country/Sub-region, 2017–2027
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Type of Treatment
13.5.2. By End-user
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competition Matrix (By Tier and Size of companies)
14.2. Global Nasal Polyps Treatment Market Position Analysis, by Company, 2018
14.3. Company Profiles
14.3.1. OptiNose US, Inc.
14.3.2. Regeneron Pharmaceuticals, Inc.
14.3.3. Merck & Co., Inc.
14.3.4. Pfizer, Inc.
14.3.5. F. Hoffmann La-Roche, Ltd.
14.3.6. Intersect ENT, Inc.
14.3.7. GlaxoSmithKline plc
14.3.8. Sanofi
14.3.9. Novartis AG
List of Tables
Table 01: Pipeline Analysis: Nasal Polyps
Table 02: Global Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by Type of Treatment, 2017–2027
Table 03: Global Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by Pharmacological Therapies, 2017–2027
Table 04: Global Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by Surgeries, 2017–2027
Table 05: Global Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027
Table 06: Global Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2027
Table 07: North America Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 08: North America Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by Type of Treatment, 2017–2027
Table 09: North America Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by Pharmacological Therapies, 2017–2027
Table 10: North America Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by Surgeries, 2017–2027
Table 11: North America Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by End-user, 2017?2027
Table 12: Europe Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 13: Europe Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by Type of Treatment, 2017–2027
Table 14: Europe Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by Pharmacological Therapies, 2017–2027
Table 15: Europe Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by Surgeries, 2017–2027
Table 16: Europe Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by End-user, 2017?2027
Table 17: Asia Pacific Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 18: Asia Pacific Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by Type of Treatment, 2017–2027
Table 19: Asia Pacific Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by Pharmacological Therapies, 2017–2027
Table 20: Asia Pacific Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by Surgeries, 2017–2027
Table 21: Asia Pacific Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by End-user, 2017?2027
Table 22: Latin America Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 23: Latin America Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by Type of Treatment, 2017–2027
Table 24: Latin America Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by Pharmacological Therapies, 2017–2027
Table 25: Latin America Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by Surgeries, 2017–2027
Table 26: Latin America Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by End-user, 2017?2027
Table 27: Middle East & Africa Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 28: Middle East & Africa Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by Type of Treatment, 2017–2027
Table 29: Middle East & Africa Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by Pharmacological Therapies, 2017–2027
Table 30: Middle East & Africa Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by Surgeries, 2017–2027
Table 31: Middle East & Africa Nasal Polyps Treatment Market Value (US$ Mn) Forecast, by End-user, 2017?2027
List of Figures
Figure 01: Global Nasal Polyps Treatment Market Snapshot
Figure 02: Global Nasal Polyps Treatment Market Value (US$ Mn) and Distribution (%), by Region, 2019 and 2027
Figure 03: Global Nasal Polyps Treatment Market Value (US$ Mn) Forecast, 2017–2027
Figure 04: Global Nasal Polyps Treatment Market Value Share (%), by Type of Treatment, 2018
Figure 05: Global Nasal Polyps Treatment Market Value Share (%), by End-user, 2018
Figure 06: Global Nasal Polyps Treatment Market Value Share (%), by Region, 2018
Figure 07: Nasal Polyps Treatment Market - Collaborations, Partnerships & New Product Launch
Figure 08: Global Nasal Polyps Treatment Market Value Share (%), by Type of Treatment, 2018 and 2027
Figure 09: Global Nasal Polyps Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Pharmacological Therapies, 2017–2027
Figure 10: Global Nasal Polyps Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Surgeries, 2017–2027
Figure 11: Global Nasal Polyps Treatment Market Attractiveness, by Type of Treatment, 2019–2027
Figure 12: Global Nasal Polyps Treatment Market Value Share (%), by End-user, 2018 and 2027
Figure 13: Global Nasal Polyps Treatment Market Attractiveness, by End-user, 2019–2027
Figure 14: Global Nasal Polyps Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospitals, 2017–2027
Figure 15: Global Nasal Polyps Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Ambulatory Surgical Centers, 2017–2027
Figure 16: Global Nasal Polyps Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Specialty Clinics, 2017–2027
Figure 17: Global Nasal Polyps Treatment Market Value Share Analysis, by Region, 2018 and 2027
Figure 18: Global Nasal Polyps Treatment Market Attractiveness Analysis, by Region, 2019–2027
Figure 19: North America Nasal Polyps Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027
Figure 20: North America Nasal Polyps Treatment Market Value Share Analysis, by Country, 2018 and 2027
Figure 21: North America Nasal Polyps Treatment Market Attractiveness Analysis, by Country, 2019–2027
Figure 22: North America Nasal Polyps Treatment Market Value Share (%), by Type of Treatment, 2018 and 2027
Figure 23: North America Nasal Polyps Treatment Market Attractiveness, by Type of Treatment, 2019–2027
Figure 24: North America Nasal Polyps Treatment Market Value Share (%), by End-user, 2018 and 2027
Figure 25: North America Nasal Polyps Treatment Market Attractiveness, by End-user, 2019–2027
Figure 26: Europe Nasal Polyps Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027
Figure 27: Europe Nasal Polyps Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 28: Europe Nasal Polyps Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 29: Europe Nasal Polyps Treatment Market Value Share (%), by Type of Treatment, 2018 and 2027
Figure 30: Europe Nasal Polyps Treatment Market Attractiveness, by Type of Treatment, 2019–2027
Figure 31: Europe Nasal Polyps Treatment Market Value Share (%), by End-user, 2018 and 2027
Figure 32: Europe Nasal Polyps Treatment Market Attractiveness, by End-user, 2019–2027
Figure 33: Asia Pacific Nasal Polyps Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027
Figure 34: Asia Pacific Nasal Polyps Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 35: Asia Pacific Nasal Polyps Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 36: Asia Pacific Nasal Polyps Treatment Market Value Share (%), by Type of Treatment, 2018 and 2027
Figure 37: Asia Pacific Nasal Polyps Treatment Market Attractiveness, by Type of Treatment, 2019–2027
Figure 38: Asia Pacific Nasal Polyps Treatment Market Value Share (%), by End-user, 2018 and 2027
Figure 39: Asia Pacific Nasal Polyps Treatment Market Attractiveness, by End-user, 2019–2027
Figure 40: Latin America Nasal Polyps Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027
Figure 41: Latin America Nasal Polyps Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 42: Latin America Nasal Polyps Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 43: Latin America Nasal Polyps Treatment Market Value Share (%), by Type of Treatment, 2018 and 2027
Figure 44: Latin America Nasal Polyps Treatment Market Attractiveness, by Type of Treatment, 2019–2027
Figure 45: Latin America Nasal Polyps Treatment Market Value Share (%), by End-user, 2018 and 2027
Figure 46: Latin America Nasal Polyps Treatment Market Attractiveness, by End-user, 2019–2027
Figure 47: Middle East & Africa Nasal Polyps Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2027
Figure 48: Middle East & Africa Nasal Polyps Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 49: Middle East & Africa Nasal Polyps Treatment Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 50: Middle East & Africa Nasal Polyps Treatment Market Value Share (%), by Type of Treatment, 2018 and 2027
Figure 51: Middle East & Africa Nasal Polyps Treatment Market Attractiveness, by Type of Treatment, 2019–2027
Figure 52: Middle East & Africa Nasal Polyps Treatment Market Value Share (%), by End-user, 2018 and 2027
Figure 53: Middle East & Africa Nasal Polyps Treatment Market Attractiveness, by End-user, 2019–2027
Figure 54: Global Nasal Polyps Treatment Market Position Analysis, by Top Company Ranking, 2018
Figure 55: OptiNose US, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Figure 56: OptiNose US, Inc., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Figure 57: Regeneron Pharmaceuticals, Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Figure 58: Regeneron Pharmaceuticals, Inc. R&D Expenses (US$ Mn) & Y-o-Y Growth (%), 2015–2018
Figure 59: Regeneron Pharmaceuticals Inc., Breakdown of Net Sales (%), by Product, 2018
Figure 60: Merck & Co., Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Figure 61: Merck & Co., Inc., Breakdown of Net Sales (%), by Business Segment, 2018
Figure 62: Merck & Co., Inc., Breakdown of Net Sales (%), by Region, 2018
Figure 63: Merck & Co., Inc., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Figure 64: Pfizer, Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Figure 65: Pfizer, Inc., Breakdown of Net Sales (%), by Business Segment, 2018
Figure 66: Pfizer, Inc., Breakdown of Net Sales (%), by Region, 2018
Figure 67: Pfizer, Inc., R&D Expenses (US$ Mn) & Y-o-Y Growth (%), 2015–2018
Figure 68: F. Hoffmann-La Roche, Ltd., Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Figure 69: F. Hoffmann-La Roche, Ltd., Breakdown of Net Sales (%), by Business Segment, 2018
Figure 70: F. Hoffmann-La Roche, Ltd., Breakdown of Net Sales (%), by Region, 2018
Figure 71: F. Hoffmann-La Roche, Ltd., R&D Expenses (US$ Mn) & Y-o-Y Growth (%), 2015–2018
Figure 72: Intersect ENT, Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Figure 73: Intersect ENT, Inc., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2018
Figure 74: GlaxoSmithKline plc, Revenue (US$ Mn) & Y-o-Y Growth (%), 2015–2018
Figure 75: GlaxoSmithKline plc, Breakdown of Net Sales (%), by Business Segment, 2018
Figure 76: GlaxoSmithKline plc, Breakdown of Net Sales (%), by Geography, 2018
Figure 77: GlaxoSmithKline plc, R&D Expenses (US$ Mn) & Y-o-Y Growth (%), 2015–2018
Figure 78: Sanofi, Revenue (US$ Mn) & Y-o-Y Growth (%), 2015–2018
Figure 79: Sanofi, Breakdown of Net Sales (%), by Business Segment, 2018
Figure 80: Sanofi, Breakdown of Net Sales (%), by Geography, 2018
Figure 81: Sanofi, R&D Expenses (US$ Mn) & Y-o-Y Growth (%), 2015–2018
Figure 82: Novartis AG, Revenue (US$ Mn) & Y-o-Y Growth (%), 2015–2018
Figure 83: Novartis AG, Breakdown of Net Sales (%), by Business Segment, 2018
Figure 84: Novartis AG, Breakdown of Net Sales (%), by Region, 2018
Figure 85: Novartis AG, R&D Expenses (US$ Mn) & Y-o-Y Growth (%), 2015–2018
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
*86 figures and 60 tables includes